MassDevice

MassDevice.com offers news and insights specifically for the medical device sector and the businesses behind it. Known as a trusted resource in the med-tech field, MassDevice.com delivers high-quality, original news coverage. Each month, it attracts over 100,000 readers via its main website and email newsletters.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#403293

United States

#149662

Health/Health

#2962

Traffic sources

Monthly visitors

Articles

A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology

5 days ago | massdevice.com | Sean Whooley

Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely.
Dexcom continues advances in AI for CGM, type 2 diabetes awareness

5 days ago | massdevice.com | Sean Whooley

As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded partnerships and more. Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Dexcom President and COO Jake Leach explained how the company continues to drive interest in its sensor platforms.
Tandem continues to deliver more options, benefits for those with diabetes

6 days ago | massdevice.com | Sean Whooley

It’s been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn’t look like slowing down any time soon. The San Diego-based automated insulin delivery system developer offers two differentiated pump platforms — the flagship t:slim X2 and the Mobi miniature durable pump — that feature sophisticated software and connectivity to the market’s leading continuous glucose monitors (CGMs). And it continues to build on them.
Breaking: Sequel to launch twiist automated insulin delivery system next month

1 week ago | massdevice.com | Sean Whooley

Sequel Med Tech announced at the American Diabetes Association’s 85th Scientific Sessions in Chicago that it plans to launch its twiist system in July. Dr. Joanna Mitri, the company’s chief medical officer, shared the update in a Product Theater session at ADA today. Mitri said the company plans to launch the automated insulin delivery system on July 7. The company had said as recently as March that it previously expected a second-quarter launch.
Data backs Medtronic MiniMed 780G for type 2, children

1 week ago | massdevice.com | Sean Whooley

Medtronic (NYSE:MDT) today shared data supporting the use of its MiniMed 780G automated insulin delivery system in a range of patients. Our sister site, Drug Delivery Business News, reports today that the medtech giant highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. Investigators shared data at the American Diabetes Association’s 85th Scientific Sessions in Chicago.
Endogenex data supports type 2 diabetes procedure

1 week ago | massdevice.com | Sean Whooley

Endogenex today reported positive findings from studies of its endoscopic procedure aimed at transforming diabetes care. Minneapolis-based Endogenex shared findings in poster presentations at the American Diabetes Association’s 85th Scientific Sessions in Chicago. The Endogenex ReCET technology uses electroporation therapy to achieve re-cellularization. It utilizes non-thermogenic pulsed electric fields (PEF) to regenerate duodenal mucosal and submucosal cells.
Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.

1 week ago | massdevice.com | Sean Whooley

Tandem Diabetes Care (Nasdaq:TNDM) today announced a new insulin pump integration with Abbott (NYSE: ABT) Abbott Laboratories Open 133.596 Day High 133.906 52 Week High 120.4 52 Week Low 88.33 CGM. Our sister site, Drug Delivery Business News, reports today that the companies agreed to pair the t:slim X2 automated insulin delivery (AID) system with the FreeStyle Libre 3 Plus continuous glucose monitor (CGM).
Abbott could pave new roads in diabetes management with dual sensor on the horizon

1 week ago | massdevice.com | Sean Whooley

About three years ago, Abbott (NYSE:ABT) announced that it had a new diabetes-related biowearable under development. The technology — a dual sensor that continuously monitors glucose and ketone levels — already had FDA breakthrough device designation. Abbott said at the time that it was set for pivotal trial use in 2023, with regulatory submissions to follow. While the sensor has yet to hit the market, it began to make waves again three years on from that initial announcement.
Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

1 week ago | massdevice.com | Sean Whooley

Abbott (NYSE: ABT) has another integration on the way for an upcoming sensor, with Ypsomed and CamDiab the latest companies to enter into an agreement. Our sister site, Drug Delivery Business News, reports today that the companies plan to pair their mylife Loop automated insulin delivery system with the Abbott dual glucose-ketone sensor, currently under development.
Johnson & Johnson MedTech launches new Volt plating systems

1 week ago | massdevice.com | Sean Whooley

Johnson & Johnson MedTech (NYSE: JNJ) Johnson & Johnson Open 154.752 Day High 155.244 52 Week High 170.27 52 Week Low 141.57 announced today that it launched new variable angle optimized locking technology (VOLT) plating systems. The launch includes VOLT distal radius (wrist) and VOLT proximal humerus 3.5 plating systems. According to a news release, the systems aim to address a critical gap in treating two common fractures.